Repurposing FDA ‐Approved Drugs to Target MTH1 for Anticancer Therapeutics
Journal of Molecular Recognition · 2025
DOI: 10.1002/jmr.70005 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Molecular Recognition, 2025. Verfasst von Aaliya Taiyab und 6 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Interdisciplinary Research in Basic Sciences, Jamia Millia Islamia, New Delhi, India. Hauptthemen laut MEDLINE: DNA Repair Enzymes, Phosphoric Monoester Hydrolases, Drug Repositioning, Antineoplastic Agents. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 76 Literaturangaben. Gefördert von: Indian Council of Medical Research, Ongoing Research Funding program, King Saud University, Riyadh, Saudi Arabia, King Saud University.
Abstract (Originalsprache)
Cancer cells exhibit elevated levels of reactive oxygen species, resulting in oxidative stress and DNA damage. To counteract this, many cancers upregulate the expression of MTH1 (MutT Homolog‐1), a crucial enzyme that detoxifies oxidised nucleotide pools. Consequently, inhibiting MTH1 is a potential therapeutic strategy for managing DNA damage and cancer cell death. Here, we conducted a comprehensive computational screening of 3800 FDA‐approved drugs to identify potential MTH1 inhibitors. Among these, Lumacaftor and Nilotinib were selected based on their strong binding affinity and pharmacokinetic profiles. Molecular dynamics simulations over 500 ns further validated the stable binding of these drugs to MTH1, suggesting their potential as effective inhibitors. Nilotinib, a well‐known tyrosine kinase inhibitor (TKI), displayed strong binding affinity ( K a = 2.5 × 10 4 ) and potent MTH1 inhibitory activity (IC 50 : 37.2 μM). Notably, this study is the first to establish the interaction between Nilotinib and MTH1, highlighting the dual potential of Nilotinib as an MTH1 inhibitor. The findings suggest that Nilotinib could be repurposed to enhance cancer therapy, particularly in combating drug resistance through the novel mechanism of MTH1 inhibition. This approach provides new avenues for tackling chemoresistance and improving therapeutic outcomes in cancer patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Centre for Interdisciplinary Research in Basic Sciences, Jamia Millia Islamia, New Delhi, India.
- Department of Biotechnology, Faculty of Life Sciences, Jamia Millia Islamia, New Delhi, India.
- Marine Integrated Biomedical Technology Center, the National Key Research Institutes in Universities, Pukyong National University, Busan, Republic of Korea.
- Department of Pharmacognosy, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia.
ORCID-Profile: Md Imtaiyaz Hassan
Förderung
- Indian Council of Medical Research
- Ongoing Research Funding program, King Saud University, Riyadh, Saudi Arabia
- King Saud University
Zitieren
APA
Taiyab, A., Sulaimani, M. N., Rathi, A., Khan, F., Hussain, A., Alajmi, M. F., & Hassan, M. I. (2025). Repurposing FDA ‐Approved Drugs to Target MTH1 for Anticancer Therapeutics. Journal of Molecular Recognition. https://doi.org/10.1002/jmr.70005
Vancouver
Taiyab A, Sulaimani MN, Rathi A, Khan F, Hussain A, Alajmi MF, et al. Repurposing FDA ‐Approved Drugs to Target MTH1 for Anticancer Therapeutics. Journal of Molecular Recognition. 2025. doi:10.1002/jmr.70005
BibTeX
@article{Taiyab2025,
author = {Taiyab, Aaliya and Sulaimani, Md Nayab and Rathi, Aanchal and Khan, Fazlurrahman and Hussain, Afzal and Alajmi, Mohamed F and Hassan, Md Imtaiyaz},
title = {Repurposing FDA ‐Approved Drugs to Target MTH1 for Anticancer Therapeutics},
journal = {Journal of Molecular Recognition},
year = {2025},
doi = {10.1002/jmr.70005}
}
EUVIMED